Co-Diagnostics, Inc.: Form 10-Q/A for the period ended Jun 30, 2020
Filed with the SEC on Nov 3, 2020 and accepted by EDGAR at Nov 3, 2020, 07:00 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-04-01 to 2020-06-30 | $24.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2020-01-01 to 2020-06-30 | $25.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2020-04-01 to 2020-06-30 | $6.0m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2020-01-01 to 2020-06-30 | $6.5m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2020-04-01 to 2020-06-30 | $18.1m | us-gaap:GrossProfit |
| Gross profit | 6 months2020-01-01 to 2020-06-30 | $19.1m | us-gaap:GrossProfit |
| Research and development | 3 months2020-04-01 to 2020-06-30 | $750.2k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2020-01-01 to 2020-06-30 | $1.2m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2020-04-01 to 2020-06-30 | $14.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2020-01-01 to 2020-06-30 | $13.6m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2020-04-01 to 2020-06-30 | $15.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months2020-01-01 to 2020-06-30 | $13.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2020-04-01 to 2020-06-30 | $0.51 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2020-01-01 to 2020-06-30 | $0.48 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2020-04-01 to 2020-06-30 | $0.54 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2020-01-01 to 2020-06-30 | $0.50 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2020-04-01 to 2020-06-30 | 29,152,222 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2020-01-01 to 2020-06-30 | 29,094,475 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2020-01-01 to 2020-06-30 | −$348.5k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2020-01-01 to 2020-06-30 | $205.3k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2020-06-30 | $18.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-06-30 | $36.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-06-30 | $38.8m | us-gaap:Assets |
| Current liabilities | At period end2020-06-30 | $3.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-06-30 | $3.1m | us-gaap:Liabilities |
| Shareholders' equity | At period end2020-06-30 | $35.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-20-020357. Last ingested by Listed: Nov 4, 2026, 18:23 ET. Listed shows no prices and gives no investment advice.